Study of dazukibart for ongoing idiopathic inflammatory myopathies
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This trial studies the long-term effects of dazukibart in people who completed an earlier study for idiopathic inflammatory myopathies (a group of rare conditions causing muscle inflammation and weakness). It helps researchers understand how well the medicine works over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed a qualifying study where you received dazukibart or a placebo up to week 52.
- You cannot have any serious medical or psychiatric condition, including recent suicidal thoughts or behaviors.
- You cannot have used other experimental drugs (besides dazukibart) within the last 30 days or 5 half-lives of that drug.
- You cannot be taking any medications that are not allowed during the study.
- You cannot have an active infection (bacterial, viral, fungal, or other).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.